Medtronic buys neurological instruments leader
This article was originally published in Clinica
Medtronic is to bolster its neurosurgical business with the acquisition of Midas Rex, a privately-owned company which produces high-speed, powered neurological instruments, for an undisclosed amount. The Fort Worth, Texas-based company expects to generate revenues of +ACQ-55 million in 1998.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.